Abstract
The association between rotavirus serotypes and severity is not well established. Analysis of a clinical trial conducted in Latin America points at more-severe disease associated with serotype G9. Thus, demonstration of efficacy against G9 will be an important asset of any rotavirus vaccine to be introduced into a Latin American country or any country where G9 has been shown to be prevalent.
Publication types
-
Randomized Controlled Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Diarrhea, Infantile / virology
-
Female
-
Gastroenteritis / virology
-
Humans
-
Infant
-
Latin America / epidemiology
-
Male
-
Prevalence
-
Rotavirus / classification*
-
Rotavirus Infections / epidemiology
-
Rotavirus Infections / prevention & control
-
Rotavirus Infections / virology*
-
Rotavirus Vaccines / administration & dosage
-
Serotyping
-
Severity of Illness Index